Zogenix

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.   We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA refused to accept the biotech's experimental epilepsy medication for review.

Why Zogenix Stock Is Getting Crushed Today

Zogenix Inc. shares dropped in the extended session Monday after announcing that the Food and Drug Administration did not accept a marketing application for one of its drugs.

Zogenix stock drops 25% after FDA rejects filing

News for Zogenix Stock (ZGNX)